Bachem Holding (BANB) Stock Overview
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
BANB Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Bachem Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 70.80 |
| 52 Week High | CHF 76.00 |
| 52 Week Low | CHF 48.20 |
| Beta | 0.79 |
| 1 Month Change | 9.18% |
| 3 Month Change | 1.14% |
| 1 Year Change | 40.62% |
| 3 Year Change | -28.99% |
| 5 Year Change | -21.42% |
| Change since IPO | 405.71% |
Recent News & Updates
Bachem Holding - The Purest Public Peptide Play?
We are living through a biological revolution. You see it on the balance sheets of the world’s largest pharmaceutical companies and you see it in the cultural zeitgeist.
BANB: Future Upside Will Depend On Executing Profit Margin Assumptions
Narrative Update Bachem Holding's updated analyst price target now reflects a modest recalibration in assumptions, with recent CHF 5, CHF 80, and CHF 32 target increases cited by analysts who point to slightly higher profit margin expectations and a small adjustment to the assumed P/E multiple as key drivers. Analyst Commentary Recent research updates on Bachem Holding have leaned constructive, with bullish analysts adjusting their price targets upward and citing a mix of valuation and execution factors.Recent updates
Bachem Holding - The Purest Public Peptide Play?
We are living through a biological revolution. You see it on the balance sheets of the world’s largest pharmaceutical companies and you see it in the cultural zeitgeist.BANB: Future Upside Will Depend On Executing Profit Margin Assumptions
Narrative Update Bachem Holding's updated analyst price target now reflects a modest recalibration in assumptions, with recent CHF 5, CHF 80, and CHF 32 target increases cited by analysts who point to slightly higher profit margin expectations and a small adjustment to the assumed P/E multiple as key drivers. Analyst Commentary Recent research updates on Bachem Holding have leaned constructive, with bullish analysts adjusting their price targets upward and citing a mix of valuation and execution factors.
BANB: Future Execution On Project Pipeline Will Support CHF 80 Upside Potential
Narrative Update Analyst price targets for Bachem Holding have shifted to a range of CHF 60 to CHF 80, with the upper end raised from CHF 75, as analysts reflect updated views on the company in their valuation work. Analyst Commentary Recent research updates on Bachem Holding point to a split in how analysts see the risk and reward around the stock, which feeds directly into the current CHF 60 to CHF 80 price target range.BANB: Future Execution On Growth Plans Will Support Higher CHF 80 Upside Potential
Analysts have nudged the consolidated price target for Bachem Holding to CHF 80, up CHF 5 from prior levels, citing updated assumptions for growth, profitability and a slightly lower P/E outlook that align with recent Street research moves. Analyst Commentary Street research on Bachem Holding has been mixed, with some analysts lifting price targets toward CHF 80 while others are more hesitant and keep targets closer to CHF 60.BANB: Future Execution On Pipeline Plans Will Support Higher Market Confidence
The updated analyst price target for Bachem Holding suggests a modest upward revision to fair value to CHF 78.66, with analysts citing slightly adjusted assumptions for the discount rate, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher price target as a signal that their assumptions for Bachem Holding’s future earnings and cash flows now support a fair value above the prior level, even after revisiting discount rate and P/E inputs.BANB: Future Pipeline Execution Will Drive Upside Versus Recent Cautious Views
Analysts have adjusted their fair value estimate for Bachem Holding to CHF 76.59, reflecting updated views on growth, profitability and valuation following recent price target revisions that include a CHF 32 increase from RBC Capital and a reduction to CHF 60 from Barclays. Analyst Commentary Recent research shows a split view on Bachem Holding, with some bullish analysts lifting targets and more cautious voices trimming expectations.BANB: Higher Fair Value Will Rely On Execution Of Existing Order Book
Analysts have raised their fair value estimate for Bachem Holding from CHF 100.00 to CHF 110.00, citing updated assumptions around revenue growth, profit margins and future P/E multiples that are in line with recent Street target changes, including the higher price target from RBC and the revised level from Barclays. Analyst Commentary Recent research updates around Bachem Holding give you a mixed but useful read on how the Street is thinking about valuation and execution.
BANB: Building K Execution Risks Will Limit Future Share Upside
Analysts have nudged their price target on Bachem Holding slightly lower to about CHF 60 to CHF 75, reflecting updated assumptions around discount rates, revenue growth near 21.5% and an expected future P/E close to 18.9%. They are also weighing recent research that includes a reduced CHF 60 target alongside a CHF 75 target tied to the company’s Building K expansion plans.BANB: Building K Execution Risk Will Constrain Future Upside Potential
Analysts have trimmed their average price target on Bachem Holding to CHF 60 from CHF 75, citing updated assumptions for revenue growth, profit margins and future P/E multiples that reflect a more measured outlook, even as expansion projects remain in focus. Analyst Commentary Recent street research on Bachem highlights a mix of views, with some analysts seeing potential tied to expansion projects such as Building K, while others are recalibrating expectations and price targets to reflect what they view as a more balanced risk and reward profile.BANB Building K Expansion Will Define Future Upside And Execution Risk
Analysts have raised their price target for Bachem Holding from approximately CHF 58 to about CHF 75, citing increased confidence in revenue growth driven by the company's Building K expansion project, despite a slightly higher discount rate and modestly lower profit margin and valuation multiples. Analyst Commentary Recent research commentary highlights a more constructive stance on Bachem Holding, with the upgraded price target to CHF 75 framed around the growth potential from the Building K expansion project.At CHF51.85, Is Bachem Holding AG (VTX:BANB) Worth Looking At Closely?
Dec 01
Bachem Holding AG's (VTX:BANB) Price In Tune With Earnings
Oct 25Building K Production Will Serve Peptide And Oligonucleotide Therapies
Bachem Holding's fair value has been revised downward, primarily reflecting slight declines in both its discount rate and future P/E ratio, with the consensus analyst price target decreasing from CHF77.88 to CHF74.70. What's in the News Maintained 2026 sales guidance of over CHF 1 billion and profitability above 30%.Bachem Holding (VTX:BANB) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18Bachem Holding (VTX:BANB) Seems To Use Debt Quite Sensibly
Aug 16Bachem Holding's (VTX:BANB) Profits May Not Reveal Underlying Issues
Jul 30Bachem Holding AG's (VTX:BANB) P/E Is Still On The Mark Following 28% Share Price Bounce
Jul 25Bachem Holding AG's (VTX:BANB) Share Price Matching Investor Opinion
May 15
Building K And 24-Hour Operations Will Improve Efficiency
Capacity expansion and 24/7 operations enhance production, reduce costs, and bolster revenue growth in response to rising demand for peptides and oligonucleotides.Shareholder Returns
| BANB | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 4.7% | -2.6% | -0.9% |
| 1Y | 40.6% | -13.7% | 8.3% |
Return vs Industry: BANB exceeded the Swiss Life Sciences industry which returned -15% over the past year.
Return vs Market: BANB exceeded the Swiss Market which returned 7.3% over the past year.
Price Volatility
| BANB volatility | |
|---|---|
| BANB Average Weekly Movement | 6.7% |
| Life Sciences Industry Average Movement | 5.6% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in CH Market | 8.3% |
| 10% least volatile stocks in CH Market | 2.2% |
Stable Share Price: BANB's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: BANB's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 2,363 | Anne-Kathrin Stoller | www.bachem.com |
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services.
Bachem Holding AG Fundamentals Summary
| BANB fundamental statistics | |
|---|---|
| Market cap | CHF 5.31b |
| Earnings (TTM) | CHF 148.79m |
| Revenue (TTM) | CHF 695.07m |
Is BANB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BANB income statement (TTM) | |
|---|---|
| Revenue | CHF 695.07m |
| Cost of Revenue | CHF 495.34m |
| Gross Profit | CHF 199.73m |
| Other Expenses | CHF 50.94m |
| Earnings | CHF 148.79m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Jul 30, 2026
| Earnings per share (EPS) | 1.99 |
| Gross Margin | 28.74% |
| Net Profit Margin | 21.41% |
| Debt/Equity Ratio | 3.9% |
How did BANB perform over the long term?
See historical performance and comparisonDividends
Does BANB pay a reliable dividends?
See BANB dividend history and benchmarks| Bachem Holding dividend dates | |
|---|---|
| Ex Dividend Date | May 04 2026 |
| Dividend Pay Date | May 06 2026 |
| Days until Ex dividend | 3 days |
| Days until Dividend pay date | 5 days |
Does BANB pay a reliable dividends?
See BANB dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/30 06:11 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bachem Holding AG is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Pitman | Barclays |
| Charles Pitman | Barclays |
| Estelle Bétrisey | Berenberg |